文献速递细菌感染、耐药与抗菌药物

头孢吡肟-他尼硼巴坦:抗多重耐药菌的新型复方

Cefepime-Taniborbactam-a Novel Combination Therapy for Multidrug-Resistant Pathogens.
PubMed 文献 · J Infect Dis · 2025-01-01

该综述介绍新型双环硼酸酯β-内酰胺酶抑制剂他尼硼巴坦(taniborbactam)与头孢吡肟组成的复方,其对Ambler A、B、C、D类酶(含丝氨酸酶和金属β-内酰胺酶)具有强效、选择性、直接抑制作用,抑制谱广于现有β-内酰胺酶抑制剂,复方已进入后期临床开发。

要点

  • 他尼硼巴坦对Ambler A、B、C、D类β-内酰胺酶均有直接抑制作用,抑制谱广于现有抑制剂。
  • 头孢吡肟-他尼硼巴坦复方已处于后期临床开发阶段。
  • 研究者正评估其对碳青霉烯耐药肺炎克雷伯菌、多重耐药铜绿假单胞菌等革兰阴性菌的活性。

核心结论

  • 他尼硼巴坦抑制谱广于现有任何β-内酰胺酶抑制剂,头孢吡肟-他尼硼巴坦复方已进入后期临床开发,用于应对多重耐药革兰阴性病原体。

研究设计与样本

  • 综述,围绕头孢吡肟-他尼硼巴坦的药物化学进展、药代动力学与药效学、抗菌谱、临床潜在用途及耐药机制展开讨论。

主要发现

  • 他尼硼巴坦对Ambler A、B、C、D类酶(含丝氨酸和金属β-内酰胺酶)具有强效、选择性、直接抑制活性。
  • 研究者正在研究该复方对肠杆菌目(如碳青霉烯耐药肺炎克雷伯菌)及已明确碳青霉烯耐药机制的多重耐药铜绿假单胞菌等革兰阴性病原体的活性。
  • 作者提出未来临床场景设想,以更好探索该新型抑制剂组合的精确应用定位。

临床怎么用

  • 综述提出未来临床场景设想,以更好探索该新型抑制剂组合的精确应用定位。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ongoing spread of antimicrobial resistance has generated an urgent need for new antibiotics, especially against multidrug-resistant (MDR) gram-negative pathogens. Taniborbactam (previously VNRX-5133) is a novel bicyclic boronate β-lactamase inhibitor with potent, selective, and direct inhibitory activity against Ambler class A, B, C, and D enzymes, including serine and metallo-β-lactamases. Taniborbactam has a broader spectrum of inhibition than any other current β-lactamase inhibitor. The combination of cefepime with taniborbactam is in advanced clinical development. Investigators are studying the activity of cefepime-taniborbactam against gram-negative pathogens, including Enterobacterales species like carbapenem-resistant Klebsiella pneumoniae and MDR Pseudomonas aeruginosa with characterized carbapenem resistance mechanisms. In this review, we discuss the advances in medicinal chemistry that led to the development of cefepime-taniborbactam, the pharmacokinetics and pharmacodynamics, the antimicrobial spectrum of activity, potential uses in the clinic, and mechanisms of resistance. We propose future clinical scenarios to better explore the precise niche of this novel inhibitor combination.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Watkins RR, Lemonovich TL, Vila AJ, et al. Cefepime-Taniborbactam-a Novel Combination Therapy for Multidrug-Resistant Pathogens. J Infect Dis. 2025. PMID: 40353672. doi:10.1093/infdis/jiaf203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。